Reata Pharma (RETA) Tops Q1 EPS by 94c

Reata Pharma (NASDAQ: RETA) reported Q1 EPS of ($1.16), $0.94 better than the analyst estimate of ($2.10). Revenue for the quarter came in at $944 thousand versus the consensus estimate of $1.19 million.

“We made significant progress during the first quarter of 2021 with the submission of our NDA for bardoxolone for the treatment of CKD caused by Alport syndrome coming less than four months after reporting positive results from Year 2 of our Phase 3 CARDINAL trial,” said Warren Huff, Reata’s President and Chief Executive Officer. “Alport syndrome is a devastating disease that affects 30,000 to 60,000 patients in the United States. We are pleased with the FDA’s recent decision to accept our application for filing and look forward to continuing to work with the FDA during its review of our application.”

For earnings history and earnings-related data on Reata Pharma (RETA) click here.

You May Also Be Interested In

• CalPrivate Bank names Andra Frazier as chief credit officer
• Haemonetics signs non-exclusive supply deal with CSL Plasma
• Four Tree Island Advisory calls DoubleDown $11.25 offer too low